A comparative study on efficacy, safety and tolerability of topical tofacitinib vs topical tofacitinib combined with puvasol in the management of vitiligo
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2023/12/060436
- Lead Sponsor
- Dr Rohini Rathod
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1)Patients who are clinically diagnosed cases of vitiligo
2)Both sexes – males and females
3)Age – above 12 years to 60 years
4)Body surface area involving the depigmented patches of less than 10%
5)Depigmented patches in exposed areas of the body
1)Patients having vitiligo patches in more than 10% BSA and having patches over flexure areas and genitals
2)Patients with active or latent TB
3)Patients with anaemia (Hb < 9g/dl) ,liver diseases, kidney disease, GI disease (diverticulitis, perforation ,ulcers ) , respiratory disease (ILD , COPD, pulmonary edema)
4)Patients with malignancies or lymphoproliferative disorders
5)Patients on potent immunosuppresants, biological DMARDS , H/O organ transplant
6)Patients with deranged lipid profile
7)H/O recent live vaccination
8)Age less than 12 years, pregnancy and lactation
9)Family history of melanoma/non melanoma skin cancers
10)People suffering from photosensitivity disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the clinical efficacy of topical tofacitinib vs topical tofacitinib with puvasol in vitiligo patients with respect to repigmentation of skinTimepoint: 4 months
- Secondary Outcome Measures
Name Time Method To know the safety and tolerability of topical tofacitinib vs topical tofacitinib with puvasol in treatment of vitiligo. <br/ ><br> <br/ ><br>Timepoint: 4 months